 EVLT limbs. Two GSVs in the
EVLT group reopened and five partially reopened, but no
open GSVs occurred in HL/S limbs. The authors concluded that long-term follow-up is still needed to justify
EVLA vs HL/S.
The Committee noted that four of the seven trials had
short follow-up and two trials had funding from a commercial company. Overall, the quality of evidence for safety and
early efficacy was high, but evidence for long-term effectiveness in these